MSCs not checked

Biocells Medical

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“IV infusion of 200,000,000 of neuroinduced mesynchimal stem cells at week 1 of the trial period”In the company’s words, NCT07465198 on ClinicalTrials.gov
Tested for
MSA - Multiple System Atrophy, MSA
Main trialPhase 2
“This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.”In the company’s words, NCT07465198 on ClinicalTrials.gov

Other drugs for MSA - Multiple System Atrophy

All 3 drugs for MSA - Multiple System Atrophy

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting 1 Sep 2029 Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow MSCs

Following is part of Solo: you see every change to MSCs the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in